• 1
    Austin HA III, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and bytotoxic drugs. N Engl J Med 1986; 314: 6149.
  • 2
    Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 7415.
  • 3
    Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 1996; 125: 54957.
  • 4
    Illei GG, Austin HA III, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 24857.
  • 5
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 212131.
  • 6
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 7
    Treasure T. Minimisation: the platinum standard for trials? BMJ 1998; 317: 3623.
  • 8
    Balow JE, Boumpas DT, Fessler BJ, Austin HA III. Management of lupus nephritis. Kidney Int 1996; 49 Suppl 53: S8892.
  • 9
    Morel-Maroger LM, Mery JP, Droz D, Godin M, Verroust P, Kourilsky O, et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv Nephrol Necker Hosp 1976; 6: 79118.
  • 10
    Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al, and The European Consensus Study Group for Disease Activity in SLE. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992; 10: 5417.
  • 11
    Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 97180.
  • 12
    Balow JE, Austin HA III. Maintenance therapy for lupus nephritis: something old, something new. N Engl J Med 2004; 350: 10446.
  • 13
    Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. QJM 1989; 72: 779833.
  • 14
    Gruppo Italiano per lo Studio della Nefrite Lupica. Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Am J Kidney Dis 1992; 19: 4739.
  • 15
    Austin HA III, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histological data. Kidney Int 1994; 45: 54450.
  • 16
    Austin HA III, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995; 10: 16208.
  • 17
    Lim CS, Chin HJ, Jung YC, Kim YS, Ahn C, Han JS, et al. Prognostic factors of diffuse proliferative lupus nephritis. Clin Nephrol 1999; 52: 13947.
  • 18
    Levey AS, Lan SP, Corwin HL, Kasinath BS, Lachin J, Neilson EG, et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study: results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992; 116: 11423.
  • 19
    Laitman RS, Glicklich D, Sablay LB, Grayzel AI, Barland P, Bank N. Effect of long-term normalization of serum complement levels on the course of lupus nephritis. Am J Med 1989; 87: 1328.
  • 20
    Fraenkel L, Mackenzie T, Joseph L, Kashgarian M, Hayslett JP, Esdaile JM. Response to treatment as a predictor of longterm outcome in patients with lupus nephritis. J Rheumatol 1994; 21: 20527.
  • 21
    Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al, for the Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 115662.
  • 22
    Ginzler EM, Aranow C, Buyon J, Dooley M, Merrill JT, Petri M, et al. A multicenter study of mycophenolate mofetil vs. intravenous cyclophosphamide as induction therapy for severe lupus nephritis: preliminary results [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S647.